Welcome to our dedicated page for Vitrolife news (Ticker: VTRLY), a resource for investors and traders seeking the latest updates and insights on Vitrolife stock.
Vitrolife AB (VTRLY) provides essential updates for stakeholders tracking developments in assisted reproduction technologies. This centralized resource aggregates official press releases, regulatory filings, and verified news covering the company's innovations in embryo culture systems and IVF laboratory solutions.
Investors and healthcare professionals will find timely information on product approvals, strategic partnerships, and operational milestones. The curated collection includes updates on scientific advancements, quality control initiatives, and corporate governance matters relevant to the reproductive medicine sector.
Key content categories encompass earnings reports, technology patent announcements, manufacturing facility updates, and leadership team changes. All materials maintain strict adherence to factual reporting standards, providing reliable insights into Vitrolife's role in advancing fertility treatment technologies.
Bookmark this page for streamlined access to critical updates about Vitrolife's contributions to reproductive healthcare. Check regularly for new developments in cryopreservation solutions, genetic testing integrations, and global distribution network expansions.
On March 30, 2022, Vitrolife published its Annual Report for 2021, detailing the company's financial performance and strategic initiatives. The report is accessible via their website and printed copies will be mailed to shareholders who have requested them starting the week of April 11. Patrik Tolf, the CFO, can be contacted for further inquiries. This announcement seeks to inform stakeholders about the company's financial status and maintain transparency with shareholders.
The Annual General Meeting of Vitrolife AB is scheduled for April 27, 2022, at 4:00 PM in Gothenburg, Sweden. Shareholders must register by April 19, 2022, and confirm attendance by April 21, 2022. Key proposals include a dividend of SEK 0.80 per share and the election of six Board members, including re-election of Jón Sigurdsson as Chairman. The proposed Board fee totals SEK 3,600,000, revealing an increase from the previous year. The meeting will also address amendments to the Articles of Association and authorize share issues and acquisitions.
The Board of Directors of Vitrolife AB has announced the date for its Annual General Meeting, to be held on April 27, 2022, at 4:00 PM in Gothenburg, Sweden. A formal notice will be published by March 30, 2022. This meeting provides shareholders with the opportunity to participate in decisions regarding company operations and governance.
Vitrolife AB reported strong Q4 2021 results with sales reaching SEK 514 million, a 35% year-over-year increase. Genetic Services, boosted by the Igenomix acquisition, contributed SEK 116 million in December alone. The full year sales totaled SEK 1,681 million, marking a 35% growth, with a net income of SEK 344 million. An adjusted EBITDA margin of 38% reflects solid operational performance, despite currency impacts. The Board proposed maintaining a dividend of SEK 0.80 per share.
Vitrolife invites investors to a conference call on February 16, 2022, at 10:00 a.m. CET to discuss the Report on Operations 2021. The call will feature CEO Thomas Axelsson and CFO Patrik Tolf. Participants can register 10-15 minutes prior, using the provided international dial-in numbers. The report will be released at 8:00 a.m. CET on the same day, with presentation materials available on the company's website. A recorded version of the call will be accessible for seven days after the event.
On December 30, 2021, Vitrolife AB announced the issuance of 17,251,312 new shares following a decision made at the Extraordinary General Meeting on October 20, 2021. This increase brings the total number of shares to 135,447,190 as of the announcement date. This change is part of the company's compliance with the Swedish Financial Instruments Trading Act and aims to enhance liquidity and shareholder value.
On December 7, 2021, Vitrolife's CEO Thomas Axelsson sold 38,300 shares for approximately SEK 18.7 million. This sale leaves him with 13,000 shares remaining. Axelsson cited the positive development of the share price since his acquisition in 2012 as a reason to realize part of his profit for personal financial needs. The transaction will be reported to the Swedish Financial Supervisory Authority per regulations. This announcement is mandated under the EU Market Abuse Regulation, with details provided at 10:50 am CET.
Vitrolife AB has completed the acquisition of 100% of Igenomix S.L., following regulatory approvals. The deal includes a non-cash consideration issue that increases the total number of shares from 118,195,878 to 135,447,190, resulting in a dilution of approximately 13%. For the period from January 1 to September 30, 2021, Igenomix generated revenues of EUR 91.4 million, with an adjusted EBITDA of EUR 23.3 million. The integration of Igenomix will be effective from December 1, 2021, postponing the 2021 report on operations to February 16, 2022.
Vitrolife AB has announced a prospectus for the trading of newly issued shares on Nasdaq Stockholm. This follows a non-cash issue to acquire all shares in Mendel Holdco S.L., and indirectly in Igenomix S.L.. The total number of shares will rise by 17,251,312, increasing the share capital to SEK 27,631,226.760. Existing shareholders will experience a 12.7% dilution of their capital and votes. The prospectus is now available from the Swedish Financial Supervisory Authority and the company’s website.
Vitrolife AB announces the expansion of its genomic testing kits distribution to the Asia Pacific region (excluding China). This move follows the partnership with Illumina and requires a payment of USD 3 million for expanded rights. The commercial launch of EmbryoMap occurred in Q2 of this year, expected to generate over SEK 50 million in revenue in 2022, positively impacting earnings per share.
FAQ
What is the current stock price of Vitrolife (VTRLY)?
What is the market cap of Vitrolife (VTRLY)?
